MSB 8.25% $1.05 mesoblast limited

Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-39

  1. 1,210 Posts.
    lightbulb Created with Sketch. 38
    Well because there is a concrete date which will finalise a final step to approval, of course the share is worth more today as this uncertainly has been mitigated
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.